Telix Pharmaceuticals | TLX

Stock Price
27.24
Daily Change
0.25 0.93%
Monthly
-0.48%
Yearly
125.50%
Q1 Forecast
27.15


Peers Price Chg Day Year Date
Cochlear 262.28 1.37 0.53% -21.23% Mar/14
CSL 250.05 1.56 0.63% -10.76% Mar/14
Ecofibre 0.02 -0.002 -7.69% -71.76% Mar/14
Integral Diagnostics 2.20 0.03 1.38% -1.35% Mar/14
Mesoblast 2.07 -0.01 -0.48% 483.10% Mar/14
Medical Developments International 0.66 0.01 1.54% -0.75% Mar/14
Mayne Pharma 7.22 0 0% 6.80% Mar/14
Neuren Pharmaceuticals 11.68 0.65 5.89% -42.29% Mar/14
Opthea 0.60 -0.01 -0.83% -2.44% Mar/14
Paradigm Biopharmaceuticals 0.42 0.01 2.44% 5.00% Mar/14
Pacific Edge 0.13 -0.001 -0.79% 45.35% Mar/14
Polynovo 1.23 0.05 4.24% -47.21% Mar/14
PYC Therapeutics 1.24 0.01 0.81% 55.00% Mar/14
Ramsay Health Care 33.40 0.16 0.48% -38.86% Mar/14
ResMed 35.30 0.14 0.40% 21.10% Mar/14
Sonic Healthcare 25.27 -0.09 -0.35% -9.91% Mar/14

Indexes Price Day Year Date
ASX200 7790 40.63 0.52% 1.56% Mar/14

Telix Pharmaceuticals Ltd traded at 27.24 this Friday March 14th, increasing 0.25 or 0.93 percent since the previous trading session. Looking back, over the last four weeks, Telix Pharmaceuticals gained 0.48 percent. Over the last 12 months, its price rose by 125.50 percent. Looking ahead, we forecast Telix Pharmaceuticals Ltd to be priced at 27.15 by the end of this quarter and at 26.87 in one year, according to Trading Economics global macro models projections and analysts expectations.

Telix Pharmaceuticals Limited is an Australia-based is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical devices. It develops a portfolio of clinical and commercial stage products that addresses significant unmet medical needs in oncology and rare diseases. It operates a pipeline of theranostic radiopharmaceutical product candidates with a focus in urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. It operates under four business units: Therapeutics, Precision Medicine (Diagnostics), Lightpoint (Medtech), and Telix Manufacturing Solutions (TMS). Its lead imaging product is gallium-68 (68Ga) gozetotide injection (also known as 68Ga PSMA-11 and marketed under the brand name Illuccix). Its other pipelines include TLX591, TLX592, TLX250, TLX250-CDx, TLX101, TLX101-CDx, TLX300, TLX300-CDx, TLX66, and TLX66-CDx.